X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Part D cliff ahead

By Juliet Johnson  |    June 21, 2018
Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...   Read More

Part D cliff looms for seniors, as program stability could be in jeopardy

By Juliet Johnson  |    June 18, 2018
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...   Read More

Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually

By Holly Campbell  |    May 17, 2018
Sharing a portion of negotiated rebates at the pharmacy counter could save seniors in Medicare with diabetes more than $350 annually, according to a new analysis from IHS Markit. The data also...   Read More

New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D

By Juliet Johnson  |    May 9, 2018
Today, we are launching the “Let’s Talk About Medicare” advertising campaign focused on solutions to improve affordability and predictability for seniors in Medicare Part D. Similar to how the “...   Read More

Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event

By Holly Campbell  |    May 4, 2018
Yesterday, PhRMA president and CEO Stephen J. Ubl spoke at POLITICO’s “Deconstructing the Prescription Drug Supply Chain” event, discussing the incredible new era of medicine, medicine spending...   Read More

Event tomorrow: Making the biopharmaceutical supply chain work for patients

By Katie Koziara  |    May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...   Read More

Spending on medicines grew less than one percent in 2017

By Holly Campbell  |    April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...   Read More

Patients pay the price when hospitals mark up cancer medicines

By Joe Vandigo  |    April 5, 2018
Two studies released last month reveal how hospitals across the country mark up the price of medicines and deliver a growing share of provider-administered medicines, resulting in higher costs...   Read More

Advance price notification: A transparency measure that fails patients

By Saumil Pandya and Emily Donaldson  |    March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...   Read More

New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed

By Holly Campbell  |    March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates